- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02244307
Observational Study in Patients Suffering From Benign Prostatic Hyperplasia Treated With Alpha-adrenergic Blockade
September 18, 2014 updated by: Boehringer Ingelheim
Evolution of Patients Suffering From Benign Prostatic Hyperplasia (BPH) Treated With Alpha-adrenergic Blockade (JOSEPHINE)
The primary objective of this observational study was the assessment of prognosis factors for having recourse to prostatic surgery in patients with BPH who were administered class-1 alpha blockers.
The secondary objectives were the assessment of the time from alpha-adrenergic blockade treatment initiation to surgery and the evolution of patients during the study.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Observational
Enrollment (Actual)
4561
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Genders Eligible for Study
Male
Sampling Method
Non-Probability Sample
Study Population
Patients with BPH for whom alpha-blockade treatement is indicated recruited at general practitioners
Description
Inclusion Criteria:
- Any patient with BPH for whom alpha-blocker treatment is indicated
- Patients who are already on class-1 alpha-blockers can only participate in the study if all information required is known and/or available
Exclusion Criteria:
- Patient's follow-up not possible
- Patients participating in another study
- History of BPH surgery
- Prostate cancer
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Patients with BPH treated with alpha-andrenergic blockade
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Assessment of prognosis factors for having recourse to prostatic surgery
Time Frame: up to 2 years
|
up to 2 years
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Time form alpha-adrenergic blockade treatment initiation to surgery
Time Frame: up to 2 years
|
up to 2 years
|
Occurrence of concomitant BPH diseases
Time Frame: up to 2 years
|
up to 2 years
|
Total International Prostate Symptom Score (IPSS)
Time Frame: up to 2 years
|
up to 2 years
|
Percentage of patients with ongoing BPH treatment
Time Frame: up to 2 years
|
up to 2 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
January 1, 2000
Primary Completion (Actual)
June 1, 2003
Study Registration Dates
First Submitted
September 18, 2014
First Submitted That Met QC Criteria
September 18, 2014
First Posted (Estimate)
September 19, 2014
Study Record Updates
Last Update Posted (Estimate)
September 19, 2014
Last Update Submitted That Met QC Criteria
September 18, 2014
Last Verified
September 1, 2014
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 527.28
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Prostatic Hyperplasia
-
GlaxoSmithKlineCompletedBenign Prostatic Hyperplasia
-
St. Joseph's Healthcare HamiltonOntario Ministry of Health and Long Term CareCompletedBenign Prostatic HyperplasiaCanada
-
Assiut UniversityNot yet recruiting
-
NeoTract, Inc.Not yet recruitingBenign Prostatic Hyperplasia
-
Assiut UniversityNot yet recruitingBenign Prostatic Hyperplasia
-
Second Affiliated Hospital, School of Medicine,...RecruitingBenign Prostatic HyperplasiaChina
-
Jewish General HospitalNot yet recruitingBenign Prostatic Hyperplasia
-
Zenflow, Inc.RecruitingBenign Prostatic HyperplasiaAustralia, New Zealand
-
REMD Medical TechnologyRenJi Hospital; Tongji Hospital; Qilu Hospital of Shandong University; Sun Yat-Sen... and other collaboratorsCompletedBenign Prostatic HyperplasiaChina
-
Bioaraba Health Research InstituteCompletedBenign Prostatic HyperplasiaSpain
Clinical Trials on alpha-adrenergic blocker
-
Gangnam Severance HospitalRecruitingProstatic Hyperplasia | Prostatic Hypertrophy | Prostate HyperplasiaKorea, Republic of
-
Johns Hopkins UniversityFast GrantsTerminated
-
Assaf-Harofeh Medical CenterUnknownNephrolithiasis | Urolithiasis | UreterolithiasisIsrael
-
Diskapi Teaching and Research HospitalUnknown
-
KYU-SUNG LEEAstellas Pharma Korea, Inc.CompletedUrinary Bladder, OveractiveKorea, Republic of
-
Boston Scientific CorporationRecruitingBenign Prostatic Hyperplasia (BPH)France, Australia
-
Samsung Medical CenterCompletedBenign Prostatic HyperplasiaKorea, Republic of
-
Federico II UniversityCompletedAcute Coronary SyndromeItaly
-
Vanderbilt University Medical CenterRecruitingHealthy | Obesity | Insulin ResistanceUnited States
-
Uppsala UniversityKarolinska Institutet; Oslo University Hospital; Göteborg University; New York... and other collaboratorsTerminatedMyocardial Infarction With Non-obstructive Coronary ArteriesNorway, Sweden, Australia, New Zealand, Spain